Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
* Shares of Vir Biotechnology rise 11.7% to $11.85 premarket * Co inks collaboration and license agreement with Gilead for three candidates targeting selected solid tumor-associated antigens * VIR will be eligible to receive up to $135 million in total upfront and near-term preclinical milestone payments, and has the p
For best results when printing this announcement, please click on link below: Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN(®) Dual-masked T-cell Engagers for Solid Tumors - Collaboration combines Vir Biotechnology’s T-cell engager
The collaboration will discover and engineer three PRO-XTEN dual-masked T-cell engager development candidates targeting selected solid tumor-associated antigens. Gilead will have an exclusive license to…